Abstract
Sacubitril/valsartan (SAC/VAL) and angiotensin receptor blockers (ARB) are recommended therapy for heart failure with preserved ejection fraction (HFpEF), but little is known about their real-world comparative effectiveness and costs. We aimed to assess comparative effectiveness of SAC/VAL vs. ARB for preventing HF-related and all-cause hospitalizations in patients with HFpEF and their related medical costs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
